FDA Experts Back 'Operation Trialblazer' But Warn Agency Still Needs Stability
FDA regulatory experts broadly praised the agency's new "Operation Trialblazer" initiative as an important step toward accelerating drug development but cautioned that lingering leadership turnover and regulatory uncertainty continue to weigh on investment in biotechnology, particularly in the cell and gene therapy sector.
During the latest episode of the FDA Watch podcast, Arnold & Porter life sciences group chair Dan Kracov and former FDA Office of Orphan Products Development director and now Hyman, Phelps & McNamara director Gayatri Rao discussed the agency's evolving regulatory priorities under acting FDA commissioner Kyle Diamantas. The discussion also touched on the release of additional complete response letters, advances in AI-enabled medical devices, proposed changes to food ingredient regulation, and broader policy developments across the agency.
Both experts described Operation Trialblazer — an HHS-wide initiative aimed at speeding clinical development through expedited IND reviews, streamlined chemistry, manufacturing and controls (CMC) expectations, expanded use of innovative clinical trial designs, and closer coordination across agencies—as a welcome development.
Kracov said the initiative addresses a longstanding need to modernize drug development as U.S. biotechnology faces increasing global competition. He highlighted proposed flexibility around early-stage CMC requirements and greater use of basket trials, platform trials, master protocols, contract research organizations and academic medical centers to accelerate first-in-human studies. "It's really just a start, but I think we need to go there, or the current system is just not sustainable anymore," he said.
Rao agreed the initiative is "a really good, necessary and important start," but said its success will depend on implementation. She pointed to FDA guidance clarifying IND expectations and efforts to reduce unnecessary animal testing while noting that industry is awaiting details on how the expedited IND pilot program will operate.
The discussion also focused on continued leadership changes at FDA. Rao praised career staff for maintaining agency operations despite significant turnover over the past 18 months, saying acting leaders at both CDER and CBER have sought to restore stability. She noted, however, that uncertainty remains within CBER, including vacancies in key leadership positions overseeing cell and gene therapies.
Kracov said the agency has experienced an unusually high level of leadership churn and warned that political involvement has complicated regulatory decision-making. While he expressed hope that FDA is entering a period of greater stability, he said it remains unclear whether that will continue beyond the 2026 midterm elections. He advised companies to document interactions carefully, rely on scientific evidence and be prepared to challenge inconsistent regulatory decisions when necessary.
Asked about orphan drug development, Rao said FDA continues to prioritize treatments for rare diseases, citing the reauthorization of the rare pediatric disease priority review voucher program as an important incentive. However, she noted that rare disease programs often become the focus of regulatory debates because they require greater flexibility in evaluating limited clinical data. She urged companies to remain focused on science while carefully considering when to escalate disagreements within FDA or to HHS leadership.
The experts said the cell and gene therapy field has been among the hardest hit by recent regulatory uncertainty. Rao said unexpected complete response letters and shifting regulatory expectations have created "whiplash" for developers, while renewed use of advisory committee meetings suggests FDA is placing increased scrutiny on these products. She said investors are seeking greater regulatory certainty before committing additional capital.
"I think what the industry needs is they're looking for stability, they're looking for certainty," Rao said. "Until the market sees some stability and certainty, there's going to be some skittishness about wanting to invest in this area."
Kracov agreed the field remains strategically important despite recent setbacks. He said FDA is beginning to rebuild infrastructure needed to support gene and cell therapies and argued that the sector should remain a national priority, while emphasizing that manufacturing challenges and treatment costs must still be addressed to realize the technology's full potential.
The discussion also expanded to broader policy issues, including growing U.S. concern over China's biotechnology industry. Kracov said competition from China has become a bipartisan policy priority and argued that initiatives such as Operation Trialblazer should be viewed as part of a broader effort to strengthen the competitiveness of the U.S. life sciences sector. Rather than relying primarily on restrictions on collaboration with Chinese companies, he said policymakers should consider tax incentives, research support and other industrial policy measures to bolster domestic innovation. Rao added that Chinese biotechnology companies are increasingly generating early clinical data that U.S. companies can license to accelerate development programs, underscoring the need for the United States to act quickly.
The panelists were also skeptical that the administration's effort to significantly curtail direct-to-consumer prescription drug advertising would ultimately succeed. Kracov said existing First Amendment precedent and digital technologies that provide immediate access to prescribing information make broad advertising restrictions difficult to sustain. Rao added that patients increasingly supplement television advertisements by seeking additional information through AI tools, changing how consumers interact with pharmaceutical marketing.